Latest Asx And Nzx News

SkyCity has reiterated its FY27 earnings outlook after first-quarter trading remained in line with expectations, despite subdued consumer conditions in New Zealand and Australia. Cost savings are running ahead of schedule, but one-off charges, online casino investment and the absence of formal guidance leave the recovery heavily execution-dependent.

Vulcan Steel has carried its FY26 recovery into the new year, reporting a 39% lift in first-quarter revenue and a 51% increase in EBITDA. The company also raised its FY26 dividend, while cautioning that Australia and New Zealand’s recovery remains gradual and uneven.

Minerals Exploration has expanded its New Zealand exploration pipeline after broad gold intersections at Jubilee South and high-grade tungsten results at Invincible. The next phase is more ambitious, but A$1.96 million in cash covers only 1.91 quarters at the latest spending rate.

Santana Minerals has moved the Bendigo-Ophir Gold Project closer to development, with a draft Fast-track Approvals decision expected in the December quarter and a competitive project debt process now underway. Strong Rise and Shine drilling and an A$179.7 million quarter-end cash balance provide further support, although construction remains conditional on approvals, financing and a final investment decision.

Minerals Exploration has intersected broad, lower-grade gold mineralisation with higher-grade structures in four holes at Jubilee South, expanding the interpreted system toward Sovereign. The company is preparing a six-hole, 1,200-metre Sovereign program, subject to approvals, while caution remains around recovery and unproven continuity.

Blackpearl Group more than doubled annual recurring revenue to NZ$26.8 million in FY26, but the growth came alongside an NZ$17.8 million loss and a formal material uncertainty over its ability to continue as a going concern. The company says cost reductions, faster cash conversion and its refinanced BNZ facility can support the next phase.

Vulcan Steel posted a robust FY26 with revenue up 22% and NPAT rising 31%, driven by the integration of Roofing Industries and volume growth despite economic headwinds.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Minerals Exploration Limited has reported rock chip assays with gold grades up to 37.4 g/t and tungsten up to 2.63% at its Glenorchy Tungsten Project in Otago, New Zealand. The company plans a maiden drilling program in late 2026, pending regulatory approvals.

Santana Minerals has reported exceptional high-grade gold intercepts from infill drilling at its Rise and Shine orebody, including a standout 24.4m at 10.9 g/t Au and a deeper 2m section grading 89.5 g/t Au. These results enhance confidence in the deposit’s grade model and the upcoming mining schedule.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Santana Minerals has reported strong high-grade gold intercepts from initial infill drilling at its Rise and Shine deposit, bolstering confidence in the early-stage open pit mine plan and supporting upcoming financing efforts.